Chimeric antigen receptor T cell(CAR-T)therapy is one of the most promising approaches in cancer treatment.1 However,the limited availability of patient-derived T cells narrows its universal applicability.Thus,it is n...Chimeric antigen receptor T cell(CAR-T)therapy is one of the most promising approaches in cancer treatment.1 However,the limited availability of patient-derived T cells narrows its universal applicability.Thus,it is necessary to invent new methods to obtain alternative T-cell sources.Pluripotent stem cells(PSCs),which have unlimited culture potential and are amenable to gene editing,are ideal for generating induced T(iT)cells.展开更多
基金supported by the CAS Key Research Program of Frontier Sciences(QYZDB-SSW-SMC057)the Strategic Priority Research Program of Chinese Academy of Sciences(XDA16010601)+4 种基金the National Key R&D Program of China(2019YFA0110203)the Major Research and Development Project of Guangzhou Regenerative Medicine and Health Guangdong Laboratory(2018GZR110104006)the Health and Medical Care Collaborative Innovation Program of Guangzhou Scientific and Technology(201803040017)the Science and Technology Planning Project of Guangdong Province(2017B030314056)the National Natural Science Foundation of China(81925002,81970099,31900814).
文摘Chimeric antigen receptor T cell(CAR-T)therapy is one of the most promising approaches in cancer treatment.1 However,the limited availability of patient-derived T cells narrows its universal applicability.Thus,it is necessary to invent new methods to obtain alternative T-cell sources.Pluripotent stem cells(PSCs),which have unlimited culture potential and are amenable to gene editing,are ideal for generating induced T(iT)cells.
